Identification of KU-55933 as an anti-atherosclerosis compound by using a hemodynamic-based high-throughput drug screening platform
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2318718121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Shu-Yi Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 350, Taiwan. Hauptthemen laut MEDLINE: Endothelial Cells, Atherosclerosis, Morpholines, Pyrones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, HHS | National Institutes of Health, National Science and Technology Council.
Abstract (Originalsprache)
Several compounds have been used for atherosclerosis treatment, including clinical trials; however, no anti-atherosclerotic drugs based on hemodynamic force-mediated atherogenesis have been discovered. Our previous studies demonstrated that “small mothers against decapentaplegic homolog 1/5” (Smad1/5) is a convergent signaling molecule for chemical [e.g., bone morphogenetic proteins (BMPs)] and mechanical (e.g., disturbed flow) stimulations and hence may serve as a promising hemodynamic-based target for anti-atherosclerosis drug development. The goal of this study was to develop a high-throughput screening (HTS) platform to identify potential compounds that can inhibit disturbed flow- and BMP-induced Smad1/5 activation and atherosclerosis. Through HTS using a Smad1/5 downstream target inhibitor of DNA binding 1 ( Id-1 ) as a luciferase reporter, we demonstrated that KU-55933 and Apicidin suppressed Id-1 expression in AD-293 cells. KU-55933 (10 μM), Apicidin (10 μM), and the combination of half doses of each [1/2(K + A)] inhibited disturbed flow- and BMP4-induced Smad1/5 activation in human vascular endothelial cells (ECs). KU-55933, Apicidin, and 1/2(K + A) treatments caused 50.6%, 47.4%, and 73.3% inhibitions of EC proliferation induced by disturbed flow, respectively, whereas EC inflammation was only suppressed by KU-55933 and 1/2(K + A), but not Apicidin alone. Administrations of KU-55933 and 1/2(K + A) to apolipoprotein E-deficient mice inhibited Smad1/5 activation in ECs in athero-susceptible regions, thereby suppressing endothelial proliferation and inflammation, with the attenuation of atherosclerotic lesions in these mice. A unique drug screening platform has been developed to demonstrate that KU-55933 and its combination with Apicidin are promising therapeutic compounds for atherosclerosis based on hemodynamic considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 350, Taiwan.
- Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
- Department of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 93093.
- Department of Medicine, University of California, San Diego, La Jolla, CA 93093.
- College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
- Taipei Heart Institute, Taipei Medical University, Taipei 110, Taiwan.
ORCID-Profile: Shu Chien
Förderung
- NHLBI NIH HHS
- HHS | National Institutes of Health
- National Science and Technology Council
Zitieren
APA
Wei, S. Y., Fu, W. S., Liu, C. H., Wang, W. L., Shih, Y. T., Chien, S., & Chiu, J. J. (2024). Identification of KU-55933 as an anti-atherosclerosis compound by using a hemodynamic-based high-throughput drug screening platform. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2318718121
Vancouver
Wei SY, Fu WS, Liu CH, Wang WL, Shih YT, Chien S, et al. Identification of KU-55933 as an anti-atherosclerosis compound by using a hemodynamic-based high-throughput drug screening platform. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2318718121
BibTeX
@article{Wei2024,
author = {Wei, Shu-Yi and Fu, Wei-Shan and Liu, Chang-Hsuan and Wang, Wei-Li and Shih, Yu-Tsung and Chien, Shu and Chiu, Jeng-Jiann},
title = {Identification of KU-55933 as an anti-atherosclerosis compound by using a hemodynamic-based high-throughput drug screening platform},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2318718121}
}
EUVIMED